In a randomized phase II clinical study involving advanced KRAS wild‐type CRC, adding ramucirumab to irinotecan and cetuximab resulted in extended progression‐free survival, confirming its therapeutic efficacy in clinical practice [198]. Here, KRAS is linked to colorectal carcinoma.